---
schema_version: "secwatch.filing_event.v1"
accession: "0001005286-22-000083"
form_type: "8-K"
ticker: "LFCR"
cik: "0001005286"
company_name: "LIFECORE BIOMEDICAL, INC. DE"
filed_at: "2022-11-25T23:59:59+00:00"
generated_at: "2026-06-21T12:58:06.823044+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Lifecore Biomedical raises $5.0M via private placement of 627,746 shares at $7.97 each

## Summary
- Sold 627,746 shares of common stock at $7.97 each to entities affiliated with Wynnefield Capital, Inc.
- Gross proceeds of approximately $5.0 million; transaction closed November 25, 2022.
- Purchasers granted piggyback registration rights; offering exempt under Section 4(a)(2) of Securities Act.
- Shares issued as unregistered; no specific use of proceeds disclosed in the filing.
- Dilution represents about 2.1% of outstanding common stock (29.67M shares pre-offering).

## SEC filing metadata
- accession: 0001005286-22-000083
- form_type: 8-K
- ticker: LFCR
- cik: 0001005286
- company_name: LIFECORE BIOMEDICAL, INC. DE
- filed_at: 2022-11-25T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 1.01, 3.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1005286/000100528622000083/0001005286-22-000083-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1005286/000100528622000083/lndc-20221125.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001005286-22-000083
- JSON: https://secwatch.observer/filing/0001005286-22-000083.json
- Plain text: https://secwatch.observer/filing/0001005286-22-000083.txt

## Key facts
- Material Agreements
  LIFECORE BIOMEDICAL, INC. DE entered into Securities Purchase Agreement with entities affiliated with Wynnefield Capital, Inc. valued at approximately $5.0 million (effective 2022-11-25).
  - Action: entry
  - Agreement: equity purchase
  - Counterparty: entities affiliated with Wynnefield Capital, Inc.
  - Value: approximately $5.0 million
  - Effective: 2022-11-25
  source text: On November 25, 2022, Lifecore Biomedical, Inc. (the “Company”) entered into a Securities Purchase Agreement (the “Purchase Agreement”) with entities affiliated with Wynnefield Capital, Inc. (the “Purchasers”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1005286/000100528622000083/0001005286-22-000083-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.